EX-99.B 4 y62384exv99wb.txt SUPPLEMENTAL INFORMATION Exhibit 99(b) MERCK & CO., INC. CONSOLIDATED SECOND QUARTER
2Q `02 2Q `01 % CHG. ------------------------------------------------------- TOTAL SALES $ 12,809.7 $ 11,893.1 8% ------------ ------------ TOTAL COSTS, EXPENSES, & OTHER $ 10,308.7 $ 9,299.6 ------------ ------------ Materials & Production 8,292.6 7,204.8 Marketing & Administrative 1,477.8 1,637.4 Research & Development 631.2 602.4 Equity Income From Affiliates (190.2) (215.0) Other (Income)/Expense, Net 97.3 70.0 PRE-TAX INCOME $ 2,501.0 $ 2,593.5 TAXES $ 750.3 $ 778.1 TAX RATE 30.0% 30.0% NET INCOME $ 1,750.7 $ 1,815.4 -4% EPS - ASSUMING DILUTION $ 0.77 $ 0.78 -1% AVG. # SHARES - ASSUMING DILUTION 2,282.8 2,328.2
2Q `02 % CHG. VOL PX FX ------ ------ --- -- -- TOTAL SALES $12,810 8% 2 6 0 ------ ------ ---- ---- ---- Total Pharmaceutical Sales 5,190 -2% -2 1 -1 ------ ------ ---- ---- ---- U.S. 3,160 -6% -8 2 0 Foreign 2,030 3% 8 -2 -3 Other Medco Sales 7,620 16%
Exhibit 99(b) MERCK & CO., INC. CONSOLIDATED SIX MONTHS YEAR-TO-DATE
2002 2001 % CHG. ------------------------------------------------------- TOTAL SALES $ 24,979.0 $ 23,238.2 7% ------------ ------------ TOTAL COSTS, EXPENSES, & OTHER $ 20,156.5 $ 18,277.2 ------------ ------------ Materials & Production 16,273.4 14,251.3 Marketing & Administrative 2,942.5 3,143.6 Research & Development 1,161.4 1,149.8 Equity Income From Affiliates (362.0) (393.6) Other (Income)/Expense, Net 141.2 126.1 PRE-TAX INCOME $ 4,822.5 $ 4,961.0 TAXES $ 1,446.8 $ 1,488.3 TAX RATE 30.0% 30.0% NET INCOME $ 3,375.7 $ 3,472.7 -3% EPS - ASSUMING DILUTION $ 1.47 $ 1.49 -1% AVG. # SHARES - ASSUMING DILUTION 2,288.6 2,337.0
2002 % CHG. VOL PX FX ---- ------ --- -- -- TOTAL SALES $24,980 7% 3 5 -1 ------- ------- ------- ------- ------- Total Pharmaceutical Sales 10,055 -2% 1 -1 -2 ------ ------ ---- ---- ---- U.S. 6,300 -3% -3 0 0 Foreign 3,755 -1% 7 -2 -6 Other Medco Sales 14,925 15%
Exhibit 99(b) MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES SECOND QUARTER 2002 OTHER (INCOME)/EXPENSE, NET
2Q `02 2Q `01 YTD 2002 YTD 2001 ------------------------------------------ INTEREST INCOME $ (105.5) $ (129.6) $ (203.9) $ (265.7) INTEREST EXPENSE 97.5 122.7 192.8 233.4 EXCHANGE (GAINS)/LOSSES 5.3 (7.5) 2.6 (20.1) MINORITY INTERESTS 59.9 60.7 110.6 146.0 AMORTIZATION OF GOODWILL AND INTANGIBLES 51.0 80.5 102.4 161.1 Other, net (10.9) (56.8) (63.3) (128.6) -------- -------- -------- -------- TOTAL $ 97.3 $ 70.0 $ 141.2 $ 126.1 -------- -------- -------- --------
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
MERIAL 2Q`02 2Q `01 YTD 2002 YTD 2001 ------ ----- ------ -------- -------- IVOMEC, HEARTGARD, other avermectins $120 $125 $220 $235 FRONTLINE 140 125 260 240 Biologicals 100 90 185 170 Other Animal Health 45 55 90 100 Poultry Genetics 60 55 110 105 ---- ---- ---- ---- TOTAL MERIAL SALES $465 $450 $865 $850 ---- ---- ---- ----
AVENTIS PASTEUR-MSD 2Q `02 2Q `01 YTD 2002 YTD 2001 ------------------- ------ ------ -------- -------- HEPATITIS VACCINES $ 15 $ 25 $ 30 $ 50 VIRAL VACCINES 10 10 15 25 Other Vaccines 80 75 150 140 ---- ---- ---- ---- TOTAL AP-MSD SALES $105 $110 $195 $215 ---- ---- ---- ----
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS) 2002
MAIL RETAIL TOTAL ---- ------ ----- FIRST QUARTER 20 121 141 SECOND QUARTER 21 119 140 ---- ------ ----- YEAR TO DATE 41 240 281
2001
MAIL RETAIL TOTAL ---- ------ ----- FIRST QUARTER 18 120 138 SECOND QUARTER 18 115 133 ---- ------ ----- YEAR TO DATE 36 235 271
Exhibit 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
2Q `02 vs. 2Q `01 ------------------------------------------------------------------ TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------------------------------------------------------------------ VIOXX 17% $845 14% $635 24% $210 ARCOXIA N/M 5 N/M - N/M 5 VASOTEC / VASERETIC -31% 205 N/M (5) -16% 210 PRINIVIL / PRINZIDE 8% 335 11% 315 -20% 20 COZAAR / HYZAAR 11% 565 13% 255 9% 310 MEVACOR -48% 70 -52% 55 -25% 15 ZOCOR 19% 1,625 25% 1,085 10% 540 AGGRASTAT 0% 30 -40% 15 N/M 15 SINGULAIR -33% 250 -48% 155 27% 95 MAXALT -25% 60 -25% 45 -25% 15 PROPECIA -9% 50 -17% 25 0% 25 PROSCAR -17% 120 -31% 55 0% 65 PRIMAXIN -3% 150 0% 50 -5% 100 INVANZ N/M - N/M - N/M - CANCIDAS N/M 25 N/M 15 N/M 10 PEPCID -86% 15 -94% 5 -50% 10 FOSAMAX 31% 640 27% 475 43% 165 CRIXIVAN/STOCRIN -11% 85 -11% 40 -10% 45 TIMOPTIC/TIMOPTIC XE -18% 45 -67% 5 0% 40 TRUSOPT/COSOPT 14% 120 33% 60 0% 60 HEPATITIS VACCINES 6% 85 7% 80 0% 5 VIRAL VACCINES 46% 205 48% 200 0% 5 OTHER VACCINES N/M 30 N/M 15 N/M 15
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful Exhibit 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
6 MONTHS 2002 OVER 2001 -------------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ -------------------------------------------------------------------- VIOXX 24% $1,495 23% $1,115 25% $380 ARCOXIA N/M 10 N/M - N/M 10 VASOTEC / VASERETIC -29% 395 -88% 10 -19% 385 PRINIVIL / PRINZIDE -1% 665 0% 625 -20% 40 COZAAR / HYZAAR 15% 1,025 32% 480 3% 545 MEVACOR -52% 135 -56% 105 -25% 30 ZOCOR 12% 3,230 15% 2,215 6% 1,015 AGGRASTAT -8% 55 N/M 25 N/M 30 SINGULAIR 7% 720 1% 535 28% 185 MAXALT 4% 140 0% 105 17% 35 PROPECIA -5% 100 -25% 45 22% 55 PROSCAR -9% 245 -18% 115 0% 130 PRIMAXIN -8% 275 -11% 80 -7% 195 INVANZ N/M 5 N/M 5 N/M - CANCIDAS N/M 40 N/M 25 N/M 15 PEPCID -90% 30 -94% 15 -57% 15 FOSAMAX 43% 1,200 46% 905 34% 295 CRIXIVAN/STOCRIN -30% 155 -24% 65 -33% 90 TIMOPTIC/TIMOPTIC XE -26% 85 -50% 15 -18% 70 TRUSOPT/COSOPT 5% 210 0% 100 10% 110 HEPATITIS VACCINES -18% 140 -16% 130 -33% 10 VIRAL VACCINES 11% 295 16% 285 -50% 10 OTHER VACCINES N/M 40 N/M 20 N/M 20
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful